934 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Merck's (MRK) Keytruda Gets FDA Nod for Two New Indications http://www.zacks.com/stock/news/261260/mercks-mrk-keytruda-gets-fda-nod-for-two-new-indications?cid=CS-ZC-FT-261260 May 19, 2017 - Merck & Co., Inc. (MRK) announced that the FDA has approved two new indications for Keytruda (pembrolizumab), the company's anti-PD-1 therapy.
5 Reasons Why Merck (MRK) is a Good Stock to Buy Now http://www.zacks.com/stock/news/260894/5-reasons-why-merck-mrk-is-a-good-stock-to-buy-now?cid=CS-ZC-FT-260894 May 17, 2017 - It looks like a great stock to buy now.
AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study http://www.zacks.com/stock/news/260583/astrazeneca-imfinzi-positive-in-phase-iii-lung-cancer-study?cid=CS-ZC-FT-260583 May 15, 2017 - AstraZeneca PLC (AZN) recently announced positive data from a phase III PACIFIC study evaluating its oncology candidate, Imfinzi (durvalumab).
Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study http://www.zacks.com/stock/news/260392/pharma-stock-roundup-mylan-teva-q1-earnings-roche-drug-misses-in-pivotal-study?cid=CS-ZC-FT-260392 May 12, 2017 - While companies like Mylan (MYL), Allergan and Teva reported Q1 results this week, several companies provided updates on their cancer drugs.
The Zacks Analyst Blog Highlights: Merck, Barclays, Activision Blizzard, Blackstone and Tyson Foods http://www.zacks.com/stock/news/260178/the-zacks-analyst-blog-highlights-merck-barclays-activision-blizzard-blackstone-and-tyson-foods?cid=CS-ZC-FT-260178 May 11, 2017 - The Zacks Analyst Blog Highlights: Merck, Barclays, Activision Blizzard, Blackstone and Tyson Foods
Top Research Reports for Activision Blizzard, Merck and Barclays http://www.zacks.com/research-daily/113354/top-research-reports-for-activision-blizzard-merck-and-barclays?cid=CS-ZC-FT-113354 May 10, 2017 - Top Research Reports for Activision Blizzard, Merck and Barclays
3 Large Cap Drug Stocks to Buy Now http://www.zacks.com/stock/news/260150/3-large-cap-drug-stocks-to-buy-now?cid=CS-ZC-FT-260150 May 10, 2017 - Our overall "Medical" sector is up about 7.78% year-to-date, which just edges out the gains of the S&P 500. Within this broad sector, one of the better performing industries has been what we call "Large Cap Pharmaceuticals."
Top Ranked Income Stocks to Buy for May 10th http://www.zacks.com/commentary/113333/top-ranked-income-stocks-to-buy-for-may-10th?cid=CS-ZC-FT-113333 May 10, 2017 - Top Ranked Income Stocks to Buy for May 10th
3 Stocks That Could Double Your Investment https://www.fool.com/investing/2017/05/10/3-stocks-that-could-double-your-investment.aspx?source=iedfolrf0000001 May 10, 2017 - There's little better than a quick 100% gain. These stock have the potential to deliver just that.
Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up http://www.zacks.com/stock/news/260125/celldex-cldx-q1-loss-in-line-revenues-beat-shares-up?cid=CS-ZC-FT-260125 May 10, 2017 - Celldex Therapeutics, Inc. (CLDX) posted first-quarter 2017 loss of 28 cents per share, which was in line with the Zacks Consensus Estimate

Pages: 1...7980818283848586878889...94

<<<Page 84>